Felpreva

Country: European Union

Language: Danish

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

emodepside, praziquantel, Tigolaner

Available from:

Vétoquinol SA

ATC code:

QP52AA51

INN (International Name):

emodepside, praziquantel, tigolaner

Therapeutic group:

Katte

Therapeutic area:

Anthelmintics,

Therapeutic indications:

For cats with, or at risk from, mixed parasitic infestations. The veterinary medicinal product is exclusively indicated when ectoparasites, cestodes and nematodes are targeted at the same time.

Authorization status:

autoriseret

Authorization date:

2021-11-11

Patient Information leaflet

                                19
B. INDLÆGSSEDDEL
20
INDLÆGSSEDDEL:
Felpreva spot-on, opløsning til små katte (1,0-2,5 kg)
Felpreva spot-on, opløsning til mellemstore katte (> 2,5-5,0 kg)
Felpreva spot-on, opløsning til store katte (> 5,0-8,0 kg)
1.
NAVN OG ADRESSE PÅ INDEHAVEREN AF MARKEDSFØRINGSTILLADELSEN
SAMT PÅ DEN INDEHAVER AF VIRKSOMHEDSGODKENDELSE, SOM ER
ANSVARLIG FOR BATCHFRIGIVELSE, HVIS FORSKELLIG HERFRA
Indehaver af markedsføringstilladelsen og fremstiller ansvarlig for
batchfrigivelse
Vetoquinol S.A.
Magny-Vernois
70200 Lure
Frankrig
2.
VETERINÆRLÆGEMIDLETS NAVN
Felpreva spot-on, opløsning til små katte (1,0-2,5 kg)
Felpreva spot-on, opløsning til mellemstore katte (> 2,5-5,0 kg)
Felpreva spot-on, opløsning til store katte (> 5,0-8,0 kg)
tigolaner/emodepsid/praziquantel
3.
ANGIVELSE AF DE(T) AKTIVE STOF(FER) OG ANDRE INDHOLDSSTOFFER
Hver spot-on applikator leverer:
FELPREVA SPOT-ON, OPLØSNING
VOLUMEN PER
DOSISENHED
[ML]
TIGOLANER
[MG]
EMODEPSID
[MG]
PRAZIQUANTEL
[MG]
til små katte (1,0-2,5 kg)
0,37
36,22
7,53
30,12
til mellemstore katte (> 2,5-
5,0 kg)
0,74
72,45
15,06
60,24
til store katte (> 5,0-8,0 kg)
1,18
115,52
24,01
96,05
HJÆLPESTOFFER: 2,63 mg/ml butylhydroxyanisol (E320) og 1,10 mg/ml
butylhydroxytoluen (E321)
som antioxidanter.
Spot-on, opløsning.
Klar gul til rød opløsning.
Der kan forekomme farveændring under opbevaring. Dette fænomen
påvirker ikke produktets kvalitet.
4.
INDIKATION(ER)
Til katte, der er angrebet af, eller som risikerer blandede
parasitære infektioner/ infestationer.
Veterinærlægemidlet er udelukkende indiceret, når det er målrettet
mod ektoparasitter, cestoder og
nematoder samtidigt.
Ektoparasitter

Til behandling af loppe- (_Ctenocephalides felis_) og flåt- (_Ixodes
ricinus, Ixodes holocyclus_)
angreb hos katte med øjeblikkelig og vedvarende dræbende virkning i
13 uger.

Veterinærlægemidlet kan anvendes som en del af behandlingsstrategien
mod loppebetinget
allergisk dermatit (FAD).

Til behandling af milde til moderate tilfælde af skab (forårsaget af
_N
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
BILAG I
PRODUKTRESUME
2
1.
VETERINÆRLÆGEMIDLETS NAVN
Felpreva spot-on, opløsning til små katte (1,0-2,5 kg)
Felpreva spot-on, opløsning til mellemstore katte (> 2,5-5,0 kg)
Felpreva spot-on, opløsning til store katte (> 5,0-8,0 kg)
2.
KVALITATIV OG KVANTITATIV SAMMENSÆTNING
AKTIVE STOFFER:
Hver spot-on applikator leverer:
VOLUMEN PER
DOSISENHED [ML]
TIGOLANER
EMODEPSID
PRAZIQUANTEL
Felpreva til små katte
(1,0-2,5 kg)
0,37 ml
36,22 mg
7,53 mg
30,12 mg
Felpreva til mellemstore
katte
(> 2,5-5,0 kg)
0,74 ml
72,45 mg
15,06 mg
60,24 mg
Felpreva til store katte
(> 5,0-8,0 kg)
1,18 ml
115,52 mg
24,01 mg
96,05 mg
HJÆLPESTOFFER:
2,63 mg/ml butylhydroxyanisol (E320) og 1,10 mg/ml butylhydroxytoluen
(E321) som antioxidanter.
Alle hjælpestoffer er anført under pkt. 6.1.
3.
LÆGEMIDDELFORM
Spot-on, opløsning.
Klar gul til rød opløsning.
Der kan forekomme farveændring under opbevaring. Dette fænomen
påvirker ikke produktets kvalitet.
4.
KLINISKE OPLYSNINGER
4.1
DYREARTER, SOM LÆGEMIDLET ER BEREGNET TIL
Katte.
4.2
TERAPEUTISKE INDIKATIONER MED ANGIVELSE AF DYREARTER, SOM LÆGEMIDLET
ER BEREGNET TIL
Til katte, der er angrebet af, eller som risikerer blandede
parasitære infestationer/infektioner.
Veterinærlægemidlet er udelukkende indiceret, når det er målrettet
mod ektoparasitter, cestoder og
nematoder samtidigt.
Ektoparasitter

Til behandling af loppe- (_Ctenocephalides felis_) og flåt- (_Ixodes
ricinus, Ixodes holocyclus_)
angreb hos katte med øjeblikkelig og vedvarende dræbende virkning i
13 uger.

Veterinærlægemidlet kan anvendes som en del af behandlingsstrategien
mod loppebetinget
allergisk dermatit (FAD).

Til behandling af milde til moderate tilfælde af skab (_Notoedres
cati_).
3

Til behandling af øremideinfestationer (_Otodectes cynotis_).
Gastrointestinal rundorm (nematoder)
Til behandling af infektioner med:

_Toxocara cati _(moden voksen, umoden voksen, L4 og L3)

_Toxascaris leonina_ (moden voksen, umoden voksen og L4)

_Ancylostoma tubaeforme_ (moden voksen, umod
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 08-06-2024
Summary of Product characteristics Summary of Product characteristics Bulgarian 08-06-2024
Public Assessment Report Public Assessment Report Bulgarian 21-09-2023
Patient Information leaflet Patient Information leaflet Spanish 08-06-2024
Public Assessment Report Public Assessment Report Spanish 21-09-2023
Patient Information leaflet Patient Information leaflet Czech 08-06-2024
Public Assessment Report Public Assessment Report Czech 21-09-2023
Patient Information leaflet Patient Information leaflet German 08-06-2024
Public Assessment Report Public Assessment Report German 21-09-2023
Patient Information leaflet Patient Information leaflet Estonian 08-06-2024
Public Assessment Report Public Assessment Report Estonian 21-09-2023
Patient Information leaflet Patient Information leaflet Greek 08-06-2024
Public Assessment Report Public Assessment Report Greek 21-09-2023
Patient Information leaflet Patient Information leaflet English 08-06-2024
Public Assessment Report Public Assessment Report English 21-09-2023
Patient Information leaflet Patient Information leaflet French 08-06-2024
Public Assessment Report Public Assessment Report French 21-09-2023
Patient Information leaflet Patient Information leaflet Italian 08-06-2024
Public Assessment Report Public Assessment Report Italian 21-09-2023
Patient Information leaflet Patient Information leaflet Latvian 08-06-2024
Public Assessment Report Public Assessment Report Latvian 21-09-2023
Patient Information leaflet Patient Information leaflet Lithuanian 08-06-2024
Summary of Product characteristics Summary of Product characteristics Lithuanian 08-06-2024
Public Assessment Report Public Assessment Report Lithuanian 21-09-2023
Patient Information leaflet Patient Information leaflet Hungarian 08-06-2024
Summary of Product characteristics Summary of Product characteristics Hungarian 08-06-2024
Public Assessment Report Public Assessment Report Hungarian 21-09-2023
Patient Information leaflet Patient Information leaflet Maltese 08-06-2024
Public Assessment Report Public Assessment Report Maltese 21-09-2023
Patient Information leaflet Patient Information leaflet Dutch 08-06-2024
Public Assessment Report Public Assessment Report Dutch 21-09-2023
Patient Information leaflet Patient Information leaflet Polish 08-06-2024
Public Assessment Report Public Assessment Report Polish 21-09-2023
Patient Information leaflet Patient Information leaflet Portuguese 08-06-2024
Summary of Product characteristics Summary of Product characteristics Portuguese 08-06-2024
Public Assessment Report Public Assessment Report Portuguese 21-09-2023
Patient Information leaflet Patient Information leaflet Romanian 08-06-2024
Public Assessment Report Public Assessment Report Romanian 21-09-2023
Patient Information leaflet Patient Information leaflet Slovak 08-06-2024
Public Assessment Report Public Assessment Report Slovak 21-09-2023
Patient Information leaflet Patient Information leaflet Slovenian 08-06-2024
Summary of Product characteristics Summary of Product characteristics Slovenian 08-06-2024
Public Assessment Report Public Assessment Report Slovenian 21-09-2023
Patient Information leaflet Patient Information leaflet Finnish 08-06-2024
Public Assessment Report Public Assessment Report Finnish 21-09-2023
Patient Information leaflet Patient Information leaflet Swedish 08-06-2024
Public Assessment Report Public Assessment Report Swedish 21-09-2023
Patient Information leaflet Patient Information leaflet Norwegian 08-06-2024
Summary of Product characteristics Summary of Product characteristics Norwegian 08-06-2024
Patient Information leaflet Patient Information leaflet Icelandic 08-06-2024
Summary of Product characteristics Summary of Product characteristics Icelandic 08-06-2024
Patient Information leaflet Patient Information leaflet Croatian 08-06-2024
Public Assessment Report Public Assessment Report Croatian 21-09-2023

Search alerts related to this product

View documents history